ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

9815	Companies
196884	Keywords
127953	Articles
104708	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 09/23/2025 at 22:30, 4 months 11 days ago

OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes
OSE Immunotherapeutics prend acte de la décision du Tribunal de commerce de Nantes rejetant ses demandes. Erreur matérielle identifiée dans le calcul des droits de vote. Préparation de l'Assemblée Générale le 30 septembre 2025

Biotechnologie Assemblée Générale Tribunal De Commerce OSE Immunotherapeutics Décision
PRESS RELEASE

published on 09/23/2025 at 22:30, 4 months 11 days ago

OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court
OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court regarding a shareholder action and prepares for the General Meeting on September 30, 2025, ensuring transparency and commitment

Transparency General Meeting OSE Immunotherapeutics Shareholder Action Nantes Commercial Court
BRIEF

published on 08/29/2025 at 08:05, 5 months 7 days ago

OSE Immunotherapeutics Clarifies Strategy Amid Shareholder Activism

Strategic Priorities Legal Proceedings OSE Immunotherapeutics Shareholder Activism Tedopi® And Lusvertikimab
BRIEF

published on 08/29/2025 at 08:05, 5 months 7 days ago

OSE Immunotherapeutics clarifie sa stratégie face à l'activisme des actionnaires

Priorités Stratégiques OSE Immunotherapeutics Activisme Des Actionnaires Procédures Judiciaires Tedopi® Et Lusvertikimab
PRESS RELEASE

published on 08/29/2025 at 08:00, 5 months 7 days ago

OSE Immunotherapeutics Reaffirms its Strategic Priorities and Publishes Shareholder Q&A to Restore Information Ahead of AGM
OSE Immunotherapeutics reaffirms strategic priorities with comprehensive Q&A document ahead of AGM. Company focuses on Tedopi® and Lusvertikimab programs for value creation

Strategic Priorities OSE Immunotherapeutics Lusvertikimab Shareholder Q&A Tedopi®
BRIEF

published on 08/25/2025 at 07:05, 5 months 11 days ago

OSE Immunotherapeutics : Nouvelle Gouvernance et Objectifs Stratégiques

Stratégie Gouvernance Actionnaires Biotechnologie Tedopi Et Lusvertikimab
BRIEF

published on 08/25/2025 at 07:05, 5 months 11 days ago

OSE Immunotherapeutics: New Governance and Strategic Objectives

Shareholders Biotechnology Governance Strategy Tedopi And Lusvertikimab
PRESS RELEASE

published on 08/25/2025 at 07:00, 5 months 11 days ago

OSE Immunotherapeutics Propose une Evolution de sa Gouvernance et Réaffirme ses Priorités Stratégiques à l’Approche de son Assemblée Générale Annuelle
OSE Immunotherapeutics propose une évolution de sa gouvernance et réaffirme ses priorités stratégiques. Assemblée Générale Annuelle le 30 septembre 2025 à Paris

Gouvernance Évolution Assemblée Générale Annuelle Priorités Stratégiques OSE Immunotherapeutics
PRESS RELEASE

published on 08/25/2025 at 07:00, 5 months 11 days ago

OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
OSE Immunotherapeutics announces proposed governance evolution and reaffirms strategic priorities ahead of Annual General Meeting. Company focuses on Tedopi® and Lusvertikimab to unlock full potential

Strategic Priorities Governance Evolution OSE Immunotherapeutics Lusvertikimab Tedopi
BRIEF

published on 08/20/2025 at 18:05, 5 months 16 days ago

OSE Immunotherapeutics Appoints Thomas Gidoin as CFO

Chief Financial Officer Strategic Planning Biotech Financing OSE Immunotherapeutics Thomas Gidoin

Accesswire

Published on 02/05/2026 at 21:00, 1 hour 2 minutes ago

Kidoz Welcomes CloudX Innovation Driving Fairer Mobile Advertising Auctions
Published on 02/05/2026 at 18:50, 3 hours 12 minutes ago

Athena Gold Provides Exploration Update From Nevada and Ontario
Published on 02/05/2026 at 17:35, 4 hours 27 minutes ago

Pentagon I Capital Corp. Enters into Letter Agreement to Complete Qualifying Transaction with Prospectiva Resources Ltd.
Published on 02/05/2026 at 16:40, 5 hours 22 minutes ago

Relevant Gold Appoints Larry Taddei to Board of Directors and Mal Karwowska as Strategic Advisor
Published on 02/05/2026 at 15:45, 6 hours 17 minutes ago

American Critical Minerals Recaps a Highly Successful 6 Months and Files Amended and Restated Technical Report

View all ACCESSWIRE

EQS Group

Published on 02/05/2026 at 19:27, 2 hours 34 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 02/05/2026 at 18:46, 3 hours 16 minutes ago

EQS-Adhoc: Mayr-Melnhof Karton AG: Impairment requirements impact profit for the financial year 2025
Published on 02/05/2026 at 18:09, 3 hours 52 minutes ago

Funding Circle Holdings plc: POS-Transaction in Own Shares
Published on 02/05/2026 at 17:55, 4 hours 6 minutes ago

Piramal Critical Care and Blue-Zone Technologies collaborate to capture, collect and recycle waste anaesthesia gas
Published on 02/05/2026 at 17:40, 4 hours 22 minutes ago

BROADPEAK SA: Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 01.02.26.

Les Echos

Published on 02/05/2026 at 19:24, 2 hours 37 minutes ago

Minutes of the Combined General Meeting
Published on 02/05/2026 at 19:24, 2 hours 37 minutes ago

Compte-Rendu de l’Assemblée Générale Mixte
Published on 02/05/2026 at 19:15, 2 hours 47 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 02/05/2026 at 19:15, 2 hours 47 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES JANVIER 2026
Published on 02/05/2026 at 19:15, 2 hours 47 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL

View all LES ECHOS COMFI WIRE